Clinical efficacy of the first two doses of anti-SARS-CoV-2 mRNA vaccines in solid cancer patients

被引:3
|
作者
Cona, Maria Silvia [1 ]
Riva, Agostino [2 ,3 ]
Dalu, Davide [1 ]
Gabrieli, Arianna [3 ]
Fasola, Cinzia [1 ]
Lipari, Giuseppe [3 ]
Pozza, Giacomo [2 ]
Rulli, Eliana [4 ]
Galli, Francesca [4 ]
Ruggieri, Lorenzo [1 ,5 ]
Masedu, Elsa [1 ]
Parma, Gaia [1 ]
Chizzoniti, Davide [1 ]
Gambaro, Anna [1 ]
Ferrario, Sabrina [1 ]
Antista, Maria [1 ]
De Monte, Matteo [1 ]
Tarkowski, Maciej S. [3 ]
La Verde, Nicla [1 ]
机构
[1] Sacco Hosp, ASST Fatebenefratelli Sacco, Dept Oncol, Milan, Italy
[2] Sacco Hosp, ASST Fatebenefratelli Sacco, Dept Infect Dis, Milan, Italy
[3] Univ Milan, Luigi Sacco Dept Biomed & Clin Sci DIB, Milan, Italy
[4] Ist Ric Farmacolog Mario Negri IRCCS, Lab Methodol Clin Res, Milan, Italy
[5] Univ Hosp Luigi Sacco ASST Fatebenefratelli Sacco, Dept Oncol, Via GB Grassi 74, I-20157 Milan, Italy
来源
CANCER MEDICINE | 2023年 / 12卷 / 12期
关键词
COVID-19;
D O I
10.1002/cam4.5968
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Cancer patients are frail individuals, thus the prevention of SARS-CoV-2 infection is essential. To date, vaccination is the most effective tool to prevent COVID-19. In a previous study, we evaluated the immunogenicity of two doses of mRNA-based vaccines (BNT162b2 or mRNA-1273) in solid cancer patients. We found that seroconversion rate in cancer patients without a previous exposure to SARS-CoV-2 was lower than in healthy controls (66.7% vs. 95%, p = 0.0020). The present study aimed to evaluate the clinical efficacy of the vaccination in the same population.Methods: This is a single-institution, prospective observational study. Data were collected through a predefined questionnaire through phone call in the period between the second and third vaccine dose. The primary objective was to describe the clinical efficacy of the vaccination, defined as the percentage of vaccinated subjects who did not develop symptomatic COVID-19 within 6 months after the second dose. The secondary objective was to describe the clinical features of patients who developed COVID-19.Results: From January to June 2021, 195 cancer patients were enrolled. Considering that 7 (3.59%) patients tested positive for SARS-CoV-2 and 5 developed symptomatic disease, the clinical efficacy of the vaccination was 97.4%. COVID-19 disease in most patients was mild and managed at home; only one hospitalization was recorded and no patient required hospitalization in the intensive care unit.Discussion: Our study suggests that increasing vaccination coverage, including booster doses, could improve the prevention of infection, hospitalization, serious illness, and death in the frail population of cancer patients.
引用
收藏
页码:12967 / 12974
页数:8
相关论文
共 50 条
  • [1] Clinical update on the efficacy of anti-SARS-CoV-2 mRNA vaccines in patients on the waiting list for liver transplantation and in liver transplant recipients
    Toniutto, Pierluigi
    Aghemo, Alessio
    Grossi, Paolo
    Burra, Patrizia
    DIGESTIVE AND LIVER DISEASE, 2021, 53 (10) : 1232 - 1234
  • [2] Immunogenicity and Safety of mRNA Anti-SARS-CoV-2 Vaccines in Patients with Systemic Lupus Erythematosus
    Mormile, Ilaria
    Della Casa, Francesca
    Petraroli, Angelica
    Furno, Alessandro
    Granata, Francescopaolo
    Portella, Giuseppe
    Rossi, Francesca Wanda
    de Paulis, Amato
    VACCINES, 2022, 10 (08)
  • [3] Immunogenicity and Safety of Anti-SARS-CoV-2 mRNA Vaccines in a Cohort of Patients with Hereditary Angioedema
    Mormile, Ilaria
    Gigliotti, Maria Celeste
    Petraroli, Angelica
    Cocchiaro, Antonio
    Furno, Alessandro
    Granata, Francescopaolo
    Rossi, Francesca Wanda
    Portella, Giuseppe
    de Paulis, Amato
    VACCINES, 2023, 11 (02)
  • [4] Anti-SARS-CoV-2 mRNA vaccines, their efficiency, side effects and controversies
    Kusnierczyk, Piotr
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2023, 98 (02)
  • [5] Role of Immunosuppression on Efficacy of Anti-SARS-CoV-2 Vaccines in Heart Transplanted (HT) Patients
    Masetti, M.
    Aloisio, A.
    Giovannini, L.
    Borgese, L.
    Caroccia, N.
    Pascale, R.
    Lazzarotto, T.
    Giannella, M.
    Pacini, D.
    Viale, P.
    Potena, L.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2022, 41 (04): : S177 - S177
  • [6] Efficacy, Safety and Immunogenicity of Anti-SARS-CoV-2 Vaccines in Patients with Cirrhosis: A Narrative Review
    Toutoudaki, Konstantina
    Dimakakou, Melitini
    Androutsakos, Theodoros
    VACCINES, 2023, 11 (02)
  • [7] Efficacy of Anti-Sars-Cov-2 mRNA Vaccines in Adults with Severe Acquired Aplastic Anemia with or without Allograft
    Garnier, Alice
    Le Bourgeois, Amandine
    Guillaume, Thierry
    Peterlin, Pierre
    Jullien, Maxime
    Coste-Burel, Marianne
    Bene, Marie C.
    Chevallier, Patrice
    BLOOD, 2022, 140 : 2941 - 2942
  • [8] Influence of immunosuppressive therapy on longitudinal changes in anti-SARS-CoV-2 spike protein antibodies after two doses of mRNA vaccines in patients with rheumatic diseases
    Kawazoe, Mai
    Aoki, Kotaro
    Hirose, Wataru
    Masuoka, Shotaro
    Nanki, Toshihiro
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2023, 113 : 111 - 113
  • [9] Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients
    Zaleska, Joanna
    Kwasnik, Paulina
    Paziewska, Magdalena
    Purkot, Joanna
    Szabelak, Aleksandra
    Jurek, Mateusz
    Masny, Natalia
    Dziatkiewicz, Izabela
    Pronobis-Szczylik, Bartosz
    Piebiak, Agnieszka
    Szymczyk, Agnieszka
    Jarosz-Chudzik, Katarzyna
    Bolkun, Lukasz
    Kozlowska, Katarzyna
    Piszcz, Jaroslaw
    Subocz, Edyta
    Halka, Janusz
    Bator, Michal
    Kalicinska, Elzbieta
    Wrobel, Tomasz
    Usnarska-Zubkiewicz, Lidia
    Rybka, Justyna
    Deren-Wagemann, Izabela
    Szyca-Smieszniak, Marta
    Dybko, Jaroslaw
    Hus, Iwona
    Pula, Bartosz
    Cichocka, Edyta
    Rymko, Marcin
    Zdunczyk, Dorota
    Ziarkiewicz, Mateusz
    Basak, Grzegorz Wladyslaw
    Bullinger, Lars
    Giannopoulos, Krzysztof
    INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (04) : 705 - 712
  • [10] The conundrum of current anti-SARS-CoV-2 vaccines
    Federico, Maurizio
    CYTOKINE & GROWTH FACTOR REVIEWS, 2021, 60 : 46 - 51